Metabolomics Pilot Study on Postoperative Intensive Care Acquired Muscle Weakness (MIRACLE-I Study)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Metabolomics
研究概览
简要总结
In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.
Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •invasive mechanically ventilated critically ill patient with expected intensive care unit stay > 3 days
- •postoperative patient
- •≥ 18 years old
- •American Society of Anesthesiology (ASA) classification ≥ III
排除标准
- •moribund patient
- •non-curative care (comfort care)
研究组 & 干预措施
Intensive Care Patients
Postoperative high-risk patients who have been admitted to intensive care after surgery
Operative Control patients
Elective operative patients where control blood samples and muscle ultrasound will be measured.
结局指标
主要结局
Metabolomics
时间窗: a median of 14 days
Blood Metabolome will be isolated from blood samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) using mass spectrometry.
次要结局
- Phosphoproteomics(a median of 14 days)
- Muscle histology(a median of 14 days)
研究者
Prof. Dr. Stefan Schaller, MD
Principal Investigator
Medical University of Vienna